Capricor Therapeutics Gets $2.4M In DoD Grant

Los Angeles-based biotechnology developer Capricor Therapeutics says this morning that it has received $2.4M in a grant from the U.S. Dpart of Defense. The company said the award goes towards establishing a scalable process to manufacture its CAP-2003 (Cardiosphere-Derived Cell Exosomes) product. Capricor is currently targeting the compound for treatment of cardiac conditions, including those associated with Duchenne muscular dystrophy (DMD).